Match!
Long P. Le
Harvard University
64Publications
21H-index
3,338Citations
Publications 64
Newest
#1Melissa Krystel-Whittemore (Harvard University)H-Index: 2
#2Martin S. Taylor (Harvard University)H-Index: 41
Last.Valentina Nardi (Harvard University)H-Index: 17
view all 12 authors...
Summary EWSR1 is a ‘promiscuous’ gene that can fuse with many different partner genes in phenotypically identical tumors or partner with the same genes in morphologically and behaviorally different neoplasms. Our study set out to examine the EWSR1 fusions identified at our institution over a 3-year period, using various methods, their association with specific entities and possible detection of novel partners and associations. Sixty-three consecutive cases investigated for EWSR1 gene fusions bet...
#1Julia Thierauf (Harvard University)H-Index: 4
#2Nisha Ramamurthy (Harvard University)H-Index: 1
Last.Jochen K. Lennerz (Harvard University)H-Index: 30
view all 18 authors...
#1Ju Cheng (Harvard University)H-Index: 1
#2Yi Cao (Harvard University)
Last.Anthony John Iafrate (Harvard University)H-Index: 79
view all 17 authors...
The use of liquid biopsies to identify driver mutations in patients with solid tumors holds great promise for performing targeted therapy selection, monitoring disease progression, and detecting treatment resistance mechanisms. We describe herein the development and clinical validation of a 28-gene cell-free DNA panel that targets the most common genetic alterations in solid tumors. Bioinformatic and variant filtering solutions were developed to improve test sensitivity and specificity. The pane...
#1Jochen K. Lennerz (Harvard University)H-Index: 30
#2Emily Chin (Harvard University)H-Index: 3
Last.Alice T. Shaw (Harvard University)H-Index: 64
view all 9 authors...
3079Background: ALK tyrosine kinase inhibitors (TKIs) are effective in treating advanced anaplastic lymphoma kinase (ALK) fusion-positive non-small-cell lung cancers (NSCLC), and specific ALK varia...
#1Ryan J. Schmidt (SC: University of Southern California)H-Index: 2
#2Allison Macleay (Harvard University)H-Index: 2
Last.Long P. Le (Harvard University)H-Index: 21
view all 3 authors...
Accurate genetic variant representation through nomenclature and annotation is essential for understanding functional consequence and properly noting the presence of variants across time, assays, and laboratories. Current variant calling algorithms detect single deletion–insertion variants as multiple indel and/or substitution variants from next-generation sequencing data. Consequently, these variants are separately annotated in bioinformatics pipelines, leading to inaccurate variant representat...
#1Leonardo Boiocchi (Harvard University)H-Index: 11
#2Robert P. Hasserjian (Harvard University)H-Index: 45
Last.Valentina Nardi (Harvard University)H-Index: 17
view all 10 authors...
Summary The introduction of next-generation sequencing has broadened the genetic landscape of myeloproliferative neoplasms (MPNs) beyond JAK2, MPL, and CALR. However, the biological role and clinical impact of most other mutations are not well defined. We interrogated 101 genes in 143 BCR-ABL1-negative MPNs in chronic phase from 2 large institutions. We detected SF3B1 mutations in 15 cases (10%) and set to investigate the clinical, morphologic, and molecular features of SF3B1 mutated (SF3B1+) MP...
#1William R. Jeck (Harvard University)H-Index: 15
#2Jesse Lee (Harvard University)H-Index: 5
Last.Valentina Nardi (Harvard University)H-Index: 17
view all 6 authors...
Structural chromosomal rearrangements leading to gene fusions are strong driver mutations in a variety of tumors. Identification of specific gene fusions can be essential for distinguishing benign from malignant conditions and for recognizing specific subtypes of neoplasms that can have different management and prognosis. Rapid identification of gene fusions is particularly critical for patients with acute leukemia who cannot wait more than a few days before initiating treatment and for whom tre...
#1Michael G. Zomnir (Harvard University)H-Index: 1
#2Lev Lipkin (Harvard University)H-Index: 1
Last.Jochen K. Lennerz (Harvard University)H-Index: 30
view all 15 authors...
PurposeNext-generation sequencing technologies are actively applied in clinical oncology. Bioinformatics pipeline analysis is an integral part of this process; however, humans cannot yet realize the full potential of the highly complex pipeline output. As a result, the decision to include a variant in the final report during routine clinical sign-out remains challenging.MethodsWe used an artificial intelligence approach to capture the collective clinical sign-out experience of six board-certifie...
#1Ibiayi Dagogo-Jack (Harvard University)H-Index: 14
#2Christopher G. Azzolli (Harvard University)H-Index: 1
Last.Jochen K. Lennerz (Harvard University)H-Index: 30
view all 27 authors...
PurposeTargeted therapy is the cornerstone of treatment of advanced EGFR-mutant non–small-cell lung cancer (NSCLC). Next-generation sequencing (NGS), the preferred method for genotyping, typically requires several weeks. Here, we assessed workflows designed to rapidly identify patients with actionable EGFR mutations and reduce time to initiation (TTI) of epidermal growth factor receptor (EGFR)–directed therapy.Patients and MethodsWe performed rapid testing for EGFR L858R mutations and exon 19 de...
#1Jessica J. LinH-Index: 14
#2Viola W. ZhuH-Index: 10
Last.Sai-Hong Ignatius OuH-Index: 54
view all 21 authors...
PurposeAdvanced anaplastic lymphoma kinase (ALK) fusion-positive non–small-cell lung cancers (NSCLCs) are effectively treated with ALK tyrosine kinase inhibitors (TKIs). However, clinical outcomes in these patients vary, and the benefit of TKIs is limited as a result of acquired resistance. Emerging data suggest that the ALK fusion variant may affect clinical outcome, but the molecular basis for this association is unknown.Patients and MethodsWe identified 129 patients with ALK-positive NSCLC wi...
1234567